Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors

BACKGROUND: ADP-A2M10 specific peptide enhanced affinity receptor (SPEAR) T-cells are genetically engineered autologous T-cells that express a high-affinity melanoma-associated antigen (MAGE)-A10-specific T-cell receptor (TCR) targeting MAGE-A10-positive tumors in the context of human leukocyte anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, David S., Butler, Marcus O., Pachynski, Russell K., Sullivan, Ryan, Kebriaei, Partow, Boross-Harmer, Sarah, Ghobadi, Armin, Frigault, Matthew J., Dumbrava, Ecaterina E., Sauer, Amy, Brophy, Francine, Navenot, Jean-Marc, Fayngerts, Svetlana, Wolchinsky, Zohar, Broad, Robyn, Batrakou, Dzmitry G., Wang, Ruoxi, Solis, Luisa M., Duose, Dzifa Yawa, Sanderson, Joseph P., Gerry, Andrew B., Marks, Diane, Bai, Jane, Norry, Elliot, Fracasso, Paula M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972123/
https://www.ncbi.nlm.nih.gov/pubmed/35372008
http://dx.doi.org/10.3389/fonc.2022.818679

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972123/
https://www.ncbi.nlm.nih.gov/pubmed/35372008
http://dx.doi.org/10.3389/fonc.2022.818679

Ejemplares similares